Bandeau Top Site


RHEOBLOOD, Modeling blood flow

Project leaders : Franck Nicoud (IMAG), Simon Mendes (IMAG), Manouk Abkarian (CBS2)

NUMEV Laboratories : IMAG, IES, LMGC, L2C


PARTNERS: CHU (Service de neuroradiologie du CHU Gui de Chauliac and Laboratoire d’Hématologie du CHU Saint-Eloi), CBS (Centre de Biochimie Structurale), IGF (Institut de Genomique Fonctionnelle), SYS2DIAG (Medical Diagnostic), LIBM (Laboratoire Interuniversitaire de biologie et de la motricité), HORIBA MEDICAL


The RheoBlood project will initiate the crossover from blood rheology to blood rheophysics, so that hemodynamics ceases to be a descriptive science and becomes indeed predictive. Rheophysics is used to stress that rheology is not sufficient and has to be completed by detailed microstructure description under flow. This is all the more necessary that the tremendous development of microfluidics now enables to design new biomedical devices for diagnosis and bio- engineering in general. One can mention systems to detect pathological cell, perform cell sorting, cell enrichment or phase separation. As such devices feature geometrical complexities that have never been studied before, a framework to predict blood flow in arbitrary geometries would represent a huge step further for medical applications. Currently, the development of such devices is only performed through a time and money-consuming trial and error approach. The long-term objective is thus to provide the community with a validated constitutive model for blood. The Rheoblood project focus on the study of blood as a suspension of deformable cells.

RheoBlood gathers 10 local academic, industrial and clinical groups with the ambition to take up the challenge of developing a constitutive model for blood. By providing Montpellier with a numerical and material platform dedicated to the study of blood rheophysics, RheoBlood naturally contributes to the structuration of the local community. This scientific project aims to make Montpellier a major site for the knowledge of blood flows, in terms of research, training and technology transfer to the industry and the clinical practice.